CLIOSS Implements Veeva Vault Clinical Applications to Streamline Trial Management
DIA Europe 2019 -- Veeva Systems (NYSE:VEEV) today announced that Clinical Organization for Strategies & Solutions (CLIOSS) implemented Veeva Vault eTMF and Veeva Vault CTMS to give sponsors better visibility into trial activities. With Veeva Vault clinical applications, CLIOSS is unifying its clinical systems and streamlining trial processes on a single platform to improve trial performance.
“We needed a modern system that could manage our increasingly complex trial activities,” said Cristina Davite, managing director at CLIOSS. “Veeva Vault allows us to work more efficiently with sponsors and deliver high-quality studies more quickly. Now we have a clinical solution that will help us succeed on a global scale.”
CLIOSS, a NMS Group company, is expanding to the fast-growing Chinese clinical research market through a recent merger. The contract research organization (CRO) wanted to move away from manual, paper-based processes to improve how it collaborates with sponsors in China and Europe.
Vault eTMF enables an active TMF operating model where all processes and documents are managed in one system, in real-time, as they are executed to maintain a constant state of inspection-readiness. With Vault CTMS, study teams and partners gain greater insights across the trial lifecycle for improved decision-making and study quality.
Together, Veeva Vault applications make it easy to share documents in real-time. For example, when CLIOSS team members create site monitoring visit reports in Vault CTMS, those reports are automatically available in Vault eTMF. This reduces manual data entry and improves information sharing with cross-functional teams and sponsors.
“CROs are leading a major industrywide shift to unify clinical operations for improved study execution,” said Rik Van Mol, vice president of development cloud strategy, Europe at Veeva. “Veeva Vault gives CLIOSS modern clinical applications to simplify collaboration with sponsors and drive greater efficiency across its trials.”
Veeva Vault eTMF and Vault CTMS are part of the Veeva Vault Clinical Operations Suite , which also includes Veeva Vault Study Startup , to unify clinical operations on a single cloud platform. Veeva’s suite of unified applications provides global visibility into trial activities and streamlines end-to-end clinical processes. For more information, visit veeva.com/eu/Clinical .
To learn more about how leading life sciences organizations are unifying clinical operations, visit Veeva at booth #B08 at DIA Europe 2019 , in Vienna, Austria, February 5 - 7.
For more on Veeva Vault eTMF, visit: veeva.com/eu/products/vault-etmf/
For more on Veeva Vault CTMS, visit: veeva.com/eu/products/vault-ctms/
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
Based in Nerviano, Italy, CLIOSS, a NMS Group company, operates internationally as a Contract Research Organization (CRO) for biopharmaceutical companies, biotech and research institutes, IRCCS, hospitals, and universities worldwide. Thanks to the diversified capacity of the NMS Group companies and to their long-standing and broad experience, CLIOSS’ services are flexible and range from comprehensive drug development management to assistance with specific stages of the study’s implementation or consultancy. For more information, visit clioss.com and nervianoms.com . Follow CLIOSS on LinkedIn .
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 675 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu .
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2018. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NJ-CELGENE19.7.2019 20:01:04 CEST | Press release
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease
JANSSEN19.7.2019 15:07:11 CEST | Press release
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer
CA-GILEAD-SCIENCES19.7.2019 14:32:09 CEST | Press release
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis
SCHLUMBERGER-LIMITED19.7.2019 13:02:04 CEST | Press release
Schlumberger Announces Second-Quarter 2019 Results
TX-SCHLUMBERGER-LIMITED19.7.2019 12:48:04 CEST | Press release
Schlumberger Appoints Olivier Le Peuch as CEO
WA-FLUKE-CORPORATION19.7.2019 12:02:10 CEST | Press release
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom